New Zealand markets closed

Merrimack Pharmaceuticals, Inc. (MACK)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
14.75+0.03 (+0.20%)
At close: 04:00PM EDT
14.84 +0.09 (+0.61%)
After hours: 06:02PM EDT

Merrimack Pharmaceuticals, Inc.

One Broadway
14th Floor
Cambridge, MA 02142
United States
617 720 8606
https://www.merrimack.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Gary L. Crocker M.B.A.President, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman76kN/A1952
Dr. Ulrik B. Nielsen Ph.D.Co-Founder & Independent Director72.5kN/A1972
Dr. Anthony J. Sinskey Ph.D., Sc.D.Co-Founder and Scientific Advisor4.25kN/A1940
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Merrimack Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 March 2024 is 9. The pillar scores are Audit: 8; Board: 10; Shareholder rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.